{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:44:33Z","timestamp":1794037473302,"version":"4.8.0"},"reference-count":293,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ymthe.2025.03.037","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T04:44:55Z","timestamp":1743137095000},"page":"1946-1965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["The curious case of AAV immunology"],"prefix":"10.1016","volume":"33","author":[{"given":"Allison M.","family":"Keeler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9769-4632","authenticated-orcid":false,"given":"Wei","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Ram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0097-9012","authenticated-orcid":false,"given":"Guangping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.03.037_bib1","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-Associated Defective Virus Particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.037_bib2","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","article-title":"Clades of Adeno-associated viruses are widely disseminated in human tissues","volume":"78","author":"Gao","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib3","doi-asserted-by":"crossref","first-page":"10220","DOI":"10.1073\/pnas.1001673107","article-title":"A viral assembly factor promotes AAV2 capsid formation in the nucleolus","volume":"107","author":"Sonntag","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.037_bib4","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1126\/science.aaw2900","article-title":"Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design","volume":"366","author":"Ogden","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.037_bib5","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/oxfordjournals.aje.a120897","article-title":"Epidemiology of adenovirus-associated virus infection in a nursery population","volume":"88","author":"Blacklow","year":"1968","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib6","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1073\/pnas.58.4.1410","article-title":"Isolation of adenovirus-associated viruses from man","volume":"58","author":"Blacklow","year":"1967","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.037_bib7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/oxfordjournals.aje.a121331","article-title":"A seroepidemiologic study of adenovirus-associated virus infection in infants and children","volume":"94","author":"Blacklow","year":"1971","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib8","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1128\/iai.11.6.1362-1370.1975","article-title":"Adeno-associated virus in adenovirus type 3 conjunctivitis","volume":"11","author":"Schmidt","year":"1975","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ymthe.2025.03.037_bib9","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41586-023-05949-1","article-title":"Adeno-associated virus type 2 in US children with acute severe hepatitis","volume":"617","author":"Servellita","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.037_bib10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-023-05948-2","article-title":"Adeno-associated virus 2 infection in children with non-A-E hepatitis","volume":"617","author":"Ho","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.037_bib11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/gt.2011.90","article-title":"Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia","volume":"19","author":"Li","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.03.037_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis Jeune","year":"2013","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.ymthe.2025.03.037_bib14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2015.29","article-title":"AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes","volume":"2","author":"Hui","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/hum.2023.225","article-title":"Prevalence Study of Cellular Capsid-Specific Immune Responses to AAV2, 4, 5, 8, 9, and rh10 in Healthy Donors","volume":"35","author":"Xicluna","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41434-024-00441-5","article-title":"Multicenter assessment and longitudinal study of the prevalence of antibodies and related adaptive immune responses to AAV in adult males with hemophilia","volume":"31","author":"Pabinger","year":"2024","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/hep.24625","article-title":"Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors","volume":"55","author":"Hosel","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.03.037_bib19","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/14728222.2010.501333","article-title":"Targeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses","volume":"14","author":"Huang","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ymthe.2025.03.037_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/hgtb.2019.013","article-title":"TLR9-Activating CpG-B ODN but Not TLR7 Agonists Triggers Antibody Formation to Factor IX in Muscle Gene Transfer","volume":"30","author":"Butterfield","year":"2019","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.ymthe.2025.03.037_bib21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000369273","article-title":"Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer","volume":"7","author":"Rogers","year":"2015","journal-title":"J.\u00a0Innate Immun."},{"key":"10.1016\/j.ymthe.2025.03.037_bib22","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.037_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2019.103997","article-title":"TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy","volume":"346","author":"Ashley","year":"2019","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib24","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1182\/blood-2010-10-314518","article-title":"The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.037_bib25","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.omtm.2023.01.001","article-title":"Erratum: Enhancement of Adeno-Associated Virus-Mediated Gene Therapy Using Hydroxychloroquine in Murine and Human Tissues","volume":"28","author":"Chandler","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.gt.3302527","article-title":"Intracellular trafficking of adeno-associated viral vectors","volume":"12","author":"Ding","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120474","article-title":"Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction","volume":"3","author":"Shao","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.03.037_bib28","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1016\/j.ymthe.2017.08.018","article-title":"AAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye","volume":"25","author":"Reichel","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41392-021-00687-0","article-title":"Pattern recognition receptors in health and diseases","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib30","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ymthe.2020.01.026","article-title":"Codon Modification and PAMPs in Clinical AAV Vectors: The Tortoise or the Hare?","volume":"28","author":"Wright","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib31","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.tibtech.2004.04.006","article-title":"Codon bias and heterologous protein expression","volume":"22","author":"Gustafsson","year":"2004","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib32","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1182\/blood-2016-11-751040","article-title":"Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8(+) T\u00a0cells","volume":"129","author":"Rogers","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.037_bib33","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.ymthe.2019.11.011","article-title":"Type I IFN Sensing by cDCs and CD4(+) T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8(+) T Cells","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib34","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ymthe.2023.11.029","article-title":"TLR9-independent CD8(+) T\u00a0cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling","volume":"32","author":"Kumar","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/v16101507","article-title":"Redundancy in Innate Immune Pathways That Promote CD8(+) T-Cell Responses in AAV1 Muscle Gene Transfer","volume":"16","author":"Li","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.03.037_bib36","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fmicb.2011.00194","article-title":"Innate Immune Responses to AAV Vectors","volume":"2","author":"Rogers","year":"2011","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib37","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/hum.2024.040","article-title":"Innate Immune Sensing of Adeno-Associated Virus Vectors","volume":"35","author":"Cao","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib38","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143780","article-title":"Overcoming innate immune barriers that impede AAV gene therapy vectors","volume":"131","author":"Muhuri","year":"2021","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.037_bib39","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/hum.2023.194","article-title":"Complement System Response to Adeno-Associated Virus Vector Gene Therapy","volume":"35","author":"Kropf","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib40","doi-asserted-by":"crossref","DOI":"10.1093\/glycob\/cwad074","article-title":"N-glycomic profiling of capsid proteins from Adeno-Associated Virus serotypes","volume":"34","author":"Xie","year":"2024","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymthe.2025.03.037_bib41","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ymthe.2024.02.002","article-title":"High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury","volume":"32","author":"Hordeaux","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib42","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement System Part I - Molecular Mechanisms of Activation and Regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib43","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1749-6632.1983.tb18116.x","article-title":"Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3","volume":"421","author":"Pangburn","year":"1983","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ymthe.2025.03.037_bib44","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/imr.13130","article-title":"Initiation of the alternative pathway of complement and the history of \u201ctickover\u201d","volume":"313","author":"Pangburn","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib45","first-page":"139","article-title":"Activation of complement via the alternative pathway","volume":"42","author":"Pangburn","year":"1983","journal-title":"Fed. Proc."},{"key":"10.1016\/j.ymthe.2025.03.037_bib46","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1126\/science.271.5247.348","article-title":"C3d of complement as a molecular adjuvant: bridging innate and acquired immunity","volume":"271","author":"Dempsey","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.037_bib47","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/JVI.01990-07","article-title":"Complement is an essential component of the immune response to adeno-associated virus vectors","volume":"82","author":"Zaiss","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.999021","article-title":"Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood","volume":"13","author":"Smith","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib49","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1089\/hum.2023.018","article-title":"Complement Activation by Adeno-Associated Virus-Neutralizing Antibody Complexes","volume":"34","author":"West","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib50","first-page":"3","article-title":"High-dose AAV toxicity in mice: Serotype-dependent hepatocellular damage and complement deposition and activation (ASGCT abstract 137)","volume":"31","author":"Buchlis","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib51","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1089\/hum.2024.156","article-title":"Thrombotic Microangiopathy Associated with Systemic Adeno-Associated Virus Gene Transfer: Review of Reported Cases","volume":"36","author":"Laforet","year":"2025","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib52","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1471-2164-9-178","article-title":"Major histocompatibility complex (Mhc) class Ib gene duplications, organization and expression patterns in mouse strain C57BL\/6","volume":"9","author":"Ohtsuka","year":"2008","journal-title":"BMC Genomics"},{"key":"10.1016\/j.ymthe.2025.03.037_bib53","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/mt.2015.179","article-title":"Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib54","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.omtm.2020.08.006","article-title":"High-Resolution Histological Landscape of AAV DNA Distribution in Cellular Compartments and Tissues following Local and Systemic Injection","volume":"18","author":"Zhao","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib55","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-immunol-120419-022408","article-title":"Germinal Centers","volume":"40","author":"Victora","year":"2022","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib56","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1128\/JVI.74.5.2420-2425.2000","article-title":"Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle","volume":"74","author":"Chirmule","year":"2000","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib57","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.coi.2018.02.001","article-title":"Humoral immune responses to infection: common mechanisms and unique strategies to combat pathogen immune evasion tactics","volume":"51","author":"Sebina","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fimmu.2013.00341","article-title":"Humoral Immune Response to AAV","volume":"4","author":"Calcedo","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101273","article-title":"Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies","volume":"32","author":"Chhabra","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib60","article-title":"Seroprevalence of binding and neutralizing antibodies against 18 adeno-associated virus types in patients with neuromuscular disorders","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib61","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib62","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2005-08-3229","article-title":"Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice","volume":"107","author":"Scallan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.037_bib63","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2006-04-017913","article-title":"Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.037_bib64","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.omtm.2018.02.003","article-title":"Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction","volume":"9","author":"Fitzpatrick","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib65","doi-asserted-by":"crossref","first-page":"19985","DOI":"10.1073\/pnas.1014074107","article-title":"Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21)","volume":"107","author":"Mallery","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.037_bib66","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib67","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jmv.21360","article-title":"Diverse IgG subclass responses to adeno-associated virus infection and vector administration","volume":"81","author":"Murphy","year":"2009","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib68","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41434-022-00371-0","article-title":"Immune profiling of adeno-associated virus response identifies B cell-specific targets that enable vector re-administration in mice","volume":"30","author":"Chen","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib69","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","article-title":"Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy","volume":"31","author":"Schulz","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101126","article-title":"A sensitive AAV transduction inhibition assay assists evaluation of critical factors for detection and concordance of pre-existing antibodies","volume":"31","author":"Pan","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib71","unstructured":"https:\/\/medical.biomarin.com\/en-us\/wp-content\/uploads\/sites\/2\/2023\/06\/ASGCT-2023-Poster-1-Characterization-of-pre-existing-immunity-to-AAV5-Draft-1-1.pdf?v=1.0."},{"key":"10.1016\/j.ymthe.2025.03.037_bib72","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fimmu.2014.00009","article-title":"Mapping the AAV Capsid Host Antibody Response toward the Development of Second Generation Gene Delivery Vectors","volume":"5","author":"Tseng","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib73","doi-asserted-by":"crossref","first-page":"e0125121","DOI":"10.1128\/JVI.01251-21","article-title":"Structurally Mapping Antigenic Epitopes of Adeno-associated Virus 9: Development of Antibody Escape Variants","volume":"96","author":"Emmanuel","year":"2022","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib74","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.ymthe.2023.03.032","article-title":"Structural and functional characterization of capsid binding by anti-AAV9 monoclonal antibodies from infants after SMA gene therapy","volume":"31","author":"Logan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib75","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human Immune Responses to Adeno-Associated Virus (AAV) Vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib76","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtm.2019.12.008","article-title":"Immune Response Mechanisms against AAV Vectors in Animal Models","volume":"17","author":"Martino","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib77","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.037_bib78","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1128\/JVI.72.5.4212-4223.1998","article-title":"Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers","volume":"72","author":"Jooss","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.666666","article-title":"T Cell-Mediated Immune Responses to AAV and AAV Vectors","volume":"12","author":"Ertl","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib80","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2174\/1566523054065039","article-title":"Immune responses to adeno-associated virus vectors","volume":"5","author":"Zaiss","year":"2005","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib81","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib82","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2008-07-167510","article-title":"AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T\u00a0cells","volume":"114","author":"Mingozzi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.037_bib83","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib84","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant","volume":"377","author":"George","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib85","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1089\/hum.2023.227","article-title":"Role of FoxP3(+) Regulatory T Cells in Modulating Immune Responses to Adeno-Associated Virus Gene Therapy","volume":"35","author":"Munoz-Melero","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib86","doi-asserted-by":"crossref","first-page":"16363","DOI":"10.1073\/pnas.0904514106","article-title":"Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy","volume":"106","author":"Brantly","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.037_bib87","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1172\/JCI70314","article-title":"Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression","volume":"123","author":"Mueller","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.037_bib88","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fimmu.2014.00082","article-title":"Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside","volume":"5","author":"Ferreira","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib89","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.ymthe.2017.03.029","article-title":"5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency","volume":"25","author":"Mueller","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib90","article-title":"Immune-driven gene expression loss following intramuscular AAV delivery to nonhuman primates is only transient","volume":"33","author":"Journou","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2017.05.006","article-title":"Complexity of immune responses to AAV transgene products - Example of factor IX","volume":"342","author":"Herzog","year":"2019","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib92","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1073\/pnas.1617726114","article-title":"Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for alpha-1-antitrypsin deficiency","volume":"114","author":"Calcedo","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.037_bib93","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/mt.2011.280","article-title":"Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome","volume":"20","author":"Wu","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib94","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib95","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/mthe.2001.0441","article-title":"Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9","volume":"4","author":"Fields","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib96","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1006\/mthe.2001.0442","article-title":"Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation","volume":"4","author":"Herzog","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib97","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/mt.2009.159","article-title":"Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B","volume":"17","author":"Cao","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib98","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1016\/j.ymthe.2024.08.005","article-title":"Secondary failure of lentiviral vector gene therapy in a cerebral adrenoleukodystrophy patient with an ABCD1 whole-gene deletion","volume":"32","author":"Lund","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib99","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMc2212912","article-title":"Dystrophin Immunity after Gene Therapy for Duchenne\u2019s Muscular Dystrophy","volume":"388","author":"Bonnemann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib100","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in Duchenne's muscular dystrophy","volume":"363","author":"Mendell","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib101","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2025.03.037_bib102","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1086\/428143","article-title":"2004 William Allan Award address. Cloning of the DMD gene","volume":"76","author":"Kunkel","year":"2005","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2025.03.037_bib103","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/hum.2018.012","article-title":"Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients","volume":"29","author":"Duan","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib104","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41598-024-84077-w","article-title":"Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy","volume":"15","author":"Potter","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.03.037_bib105","doi-asserted-by":"crossref","first-page":"e1010966","DOI":"10.1080\/21675511.2015.1010966","article-title":"The immune system in Duchenne muscular dystrophy: Friend or foe","volume":"3","author":"Villalta","year":"2015","journal-title":"Rare Dis."},{"key":"10.1016\/j.ymthe.2025.03.037_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9101447","article-title":"The Immune System in Duchenne Muscular Dystrophy Pathogenesis","volume":"9","author":"Tripodi","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymthe.2025.03.037_bib107","doi-asserted-by":"crossref","first-page":"299rv4","DOI":"10.1126\/scitranslmed.aaa7322","article-title":"Immune-mediated pathology in Duchenne muscular dystrophy","volume":"7","author":"Rosenberg","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib108","first-page":"3958","article-title":"Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T\u00a0cells in mice","volume":"117","author":"Lin","year":"2007","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.037_bib109","doi-asserted-by":"crossref","first-page":"11840","DOI":"10.1128\/JVI.01253-07","article-title":"Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice","volume":"81","author":"Lin","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib110","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.ymthe.2017.02.014","article-title":"The Balance between CD8(+) T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose","volume":"25","author":"Kumar","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib111","doi-asserted-by":"crossref","DOI":"10.1038\/s41434-025-00514-z","article-title":"Incomplete elimination of viral genomes is associated with chronic inflammation in nonhuman primate livers after AAV-mediated gene transfer","author":"Pichard","year":"2025","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib112","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd3438","article-title":"Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses","volume":"13","author":"Chan","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib113","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.omtm.2021.10.010","article-title":"Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells","volume":"23","author":"Arjomandnejad","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib114","first-page":"20","article-title":"Deimmunized Micro-Dystrophin Vectors Blunt Patient Immunity In Vitro & Restore Cardiac Functional Deficits In Vivo in mdx4cv DMD Mice Abstract #39","volume":"30","author":"Odom","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib115","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ymthe.2025.01.028","article-title":"Characterisation of the ocular inflammatory response to AAV reveals divergence by sex and age","volume":"33","author":"Clare","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib116","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1182\/blood-2012-05-432591","article-title":"Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice","volume":"120","author":"Cantore","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.037_bib117","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1182\/blood-2012-06-440123","article-title":"The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy","volume":"120","author":"Finn","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.037_bib118","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.18858","article-title":"Rational design of aptazyme riboswitches for efficient control of gene expression in mammalian cells","volume":"5","author":"Zhong","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.ymthe.2025.03.037_bib119","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41587-019-0357-y","article-title":"A reversible RNA on-switch that controls gene expression of AAV-delivered therapeutics in\u00a0vivo","volume":"38","author":"Zhong","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib120","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-021-03770-2","article-title":"Regulated control of gene therapies by drug-induced splicing","volume":"596","author":"Monteys","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.037_bib121","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1172\/JCI68205","article-title":"CpG-depleted adeno-associated virus vectors evade immune detection","volume":"123","author":"Faust","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.037_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.672449","article-title":"Effect of CpG Depletion of Vector Genome on CD8(+) T Cell Responses in AAV Gene Therapy","volume":"12","author":"Bertolini","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib123","doi-asserted-by":"crossref","first-page":"8732","DOI":"10.1128\/JVI.74.18.8732-8739.2000","article-title":"Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A\/D junction element","volume":"74","author":"Haberman","year":"2000","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib124","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41434-021-00296-0","article-title":"Rational engineering of a functional CpG-free ITR for AAV gene therapy","volume":"29","author":"Pan","year":"2022","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib125","doi-asserted-by":"crossref","DOI":"10.1165\/rcmb.2024-0247OC","article-title":"Novel Immune Response Evasion Strategy to Redose Adeno-associated Viral Vectors and Prolong Survival in Surfactant Protein-B Deficient Mice","author":"Kang","year":"2025","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib126","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.674242","article-title":"Novel Combinatorial MicroRNA-Binding Sites in AAV Vectors Synergistically Diminish Antigen Presentation and Transgene Immunity for Efficient and Stable Transduction","volume":"12","author":"Muhuri","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib127","article-title":"Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity","volume":"5","author":"Xiao","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.03.037_bib128","doi-asserted-by":"crossref","first-page":"189ra76","DOI":"10.1126\/scitranslmed.3005708","article-title":"In\u00a0vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib129","doi-asserted-by":"crossref","first-page":"E4812","DOI":"10.1073\/pnas.1704766114","article-title":"Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion","volume":"114","author":"Tse","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.037_bib130","doi-asserted-by":"crossref","first-page":"9281","DOI":"10.1128\/JVI.74.19.9281-9293.2000","article-title":"Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection","volume":"74","author":"Wobus","year":"2000","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib131","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2012-10-460733","article-title":"Engineered AAV vector minimizes in\u00a0vivo targeting of transduced hepatocytes by capsid-specific CD8+ T\u00a0cells","volume":"121","author":"Martino","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.037_bib132","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1172\/JCI66611","article-title":"Adeno-associated virus capsid antigen presentation is dependent on endosomal escape","volume":"123","author":"Li","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.037_bib133","doi-asserted-by":"crossref","first-page":"7827","DOI":"10.1073\/pnas.0802866105","article-title":"Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses","volume":"105","author":"Zhong","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.037_bib134","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1039\/C9SC04189C","article-title":"Chemical modification of the adeno-associated virus capsid to improve gene delivery","volume":"11","author":"Mevel","year":"2019","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ymthe.2025.03.037_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116148","article-title":"Novel chemical tyrosine functionalization of adeno-associated virus improves gene transfer efficiency in liver and retina","volume":"171","author":"Leray","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ymthe.2025.03.037_bib136","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/bit.20562","article-title":"PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization","volume":"92","author":"Lee","year":"2005","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ymthe.2025.03.037_bib137","doi-asserted-by":"crossref","DOI":"10.3390\/polym12020298","article-title":"The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation","volume":"12","author":"Hoang Thi","year":"2020","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.ymthe.2025.03.037_bib138","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/bloodadvances.2017010181","article-title":"Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors","volume":"1","author":"Meliani","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.03.037_bib139","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/gt.2016.11","article-title":"Exosome-associated AAV vector as a robust and convenient neuroscience tool","volume":"23","author":"Hudry","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib140","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.1016\/j.biomaterials.2014.05.032","article-title":"Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo","volume":"35","author":"Gy\u00f6rgy","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2025.03.037_bib141","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1038\/s41598-020-61518-w","article-title":"In\u00a0vivo engineering of lymphocytes after systemic exosome-associated AAV delivery","volume":"10","author":"Breuer","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.03.037_bib142","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00109-004-0537-0","article-title":"AAV gene transfer to the retina does not protect retrovirally transduced hepatocytes from the immune response","volume":"82","author":"Bellodi-Privato","year":"2004","journal-title":"J.\u00a0Mol. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib143","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2025.03.037_bib144","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","article-title":"Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial","volume":"374","author":"Maguire","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.03.037_bib145","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","article-title":"Long-term effect of gene therapy on Leber's congenital amaurosis","volume":"372","author":"Bainbridge","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib146","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/gt.2016.31","article-title":"Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs","volume":"23","author":"Boyd","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib147","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamaophthalmol.2018.6902","article-title":"Immune Response and Intraocular Inflammation in Patients With Leber Hereditary Optic Neuropathy Treated With Intravitreal Injection of Recombinant Adeno-Associated Virus 2 Carrying the ND4 Gene: A Secondary Analysis of a Phase 1\/2 Clinical Trial","volume":"137","author":"Bouquet","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib148","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ymthe.2018.05.025","article-title":"Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I\/IIa Trial by Intravitreal Delivery","volume":"26","author":"Cukras","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib149","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2018.06.011","article-title":"Two-Year Results After AAV2-Mediated Gene Therapy for Choroideremia: The Alberta Experience","volume":"193","author":"Dimopoulos","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib150","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41586-024-07130-8","article-title":"Compartmentalized ocular lymphatic system mediates eye-brain immunity","volume":"628","author":"Yin","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.037_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100050","article-title":"An Optimized Treatment Protocol for Subretinal Injections Limits Intravitreal Vector Distribution","volume":"1","author":"Reichel","year":"2021","journal-title":"Ophthalmol. Sci."},{"key":"10.1016\/j.ymthe.2025.03.037_bib152","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/bjo.79.9.834","article-title":"Flow cytometric identification of a minority population of MHC class II positive cells in the normal rat retina distinct from CD45lowCD11b\/c+CD4low parenchymal microglia","volume":"79","author":"Dick","year":"1995","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib153","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12974-017-0915-5","article-title":"MHC class II expression and potential antigen-presenting cells in the retina during experimental autoimmune uveitis","volume":"14","author":"Lipski","year":"2017","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ymthe.2025.03.037_bib154","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/glia.20535","article-title":"Turnover of resident retinal microglia in the normal adult mouse","volume":"55","author":"Xu","year":"2007","journal-title":"Glia"},{"key":"10.1016\/j.ymthe.2025.03.037_bib155","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1167\/iovs.06-0697","article-title":"Identification of novel dendritic cell populations in normal mouse retina","volume":"48","author":"Xu","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2025.03.037_bib156","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nm.4450","article-title":"cGAS drives noncanonical-inflammasome activation in age-related macular degeneration","volume":"24","author":"Kerur","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib157","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jneuroim.2004.04.018","article-title":"Innate immunity in the retina: Toll-like receptor (TLR) signaling in human retinal pigment epithelial cells","volume":"153","author":"Kumar","year":"2004","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib158","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1476-9255-11-20","article-title":"Role of toll-like receptors in human iris pigment epithelial cells and their response to pathogen-associated molecular patterns","volume":"11","author":"Mai","year":"2014","journal-title":"J.\u00a0Inflamm."},{"key":"10.1016\/j.ymthe.2025.03.037_bib159","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1167\/iovs.05-0956","article-title":"Toll-like receptors and the eye","volume":"47","author":"Yu","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2025.03.037_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100915","article-title":"Immune responses to retinal gene therapy using adeno-associated viral vectors - Implications for treatment success and safety","volume":"83","author":"Bucher","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ymthe.2025.03.037_bib161","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/brv.12718","article-title":"Humoral immune responses to AAV gene therapy in the ocular compartment","volume":"96","author":"Whitehead","year":"2021","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"key":"10.1016\/j.ymthe.2025.03.037_bib162","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00435","article-title":"Immune responses to central nervous system directed adeno-associated virus gene therapy: Does direct CNS delivery make a difference?","volume":"21","author":"Harkins","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ymthe.2025.03.037_bib164","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1089\/hum.2022.138","article-title":"Immune Responses and Immunosuppressive Strategies for Adeno-Associated Virus-Based Gene Therapy for Treatment of Central Nervous System Disorders: Current Knowledge and Approaches","volume":"33","author":"Prasad","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib165","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jconrel.2023.01.067","article-title":"AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges","volume":"355","author":"Kang","year":"2023","journal-title":"J.\u00a0Control Release."},{"key":"10.1016\/j.ymthe.2025.03.037_bib166","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ana.23648","article-title":"The blood-brain barrier in health and disease","volume":"72","author":"Daneman","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib167","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa2307952","article-title":"Intrathecal Gene Therapy for Giant Axonal Neuropathy","volume":"390","author":"Bharucha-Goebel","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib168","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib169","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","article-title":"AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B","volume":"101","author":"Manno","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.037_bib170","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ana.22251","article-title":"Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D","volume":"68","author":"Mendell","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib171","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.21732","article-title":"Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins","volume":"66","author":"Mendell","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib172","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/brain\/awr342","article-title":"A phase I trial of adeno-associated virus serotype 1-gamma-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C","volume":"135","author":"Herson","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2025.03.037_bib173","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1089\/hum.2011.053","article-title":"Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results","volume":"22","author":"Flotte","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib174","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/hum.2023.056","article-title":"Immune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical Studies","volume":"34","author":"Kumar","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib175","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2007-02-073304","article-title":"Induction and role of regulatory CD4+CD25+ T\u00a0cells in tolerance to the transgene product following hepatic in\u00a0vivo gene transfer","volume":"110","author":"Cao","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.037_bib176","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in\u00a0vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.037_bib177","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3389\/fimmu.2020.00618","article-title":"Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A","volume":"11","author":"Samelson-Jones","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib178","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.omtm.2019.11.010","article-title":"Liver-Directed but Not Muscle-Directed AAV-Antibody Gene Transfer Limits Humoral Immune Responses in Rhesus Monkeys","volume":"16","author":"Fuchs","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib179","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood-2007-03-080093","article-title":"Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver","volume":"110","author":"Mingozzi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.037_bib180","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.omtm.2019.08.012","article-title":"Role of Regulatory T Cell and Effector T Cell Exhaustion in Liver-Mediated Transgene Tolerance in Muscle","volume":"15","author":"Poupiot","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib181","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127008","article-title":"Dual muscle-liver transduction imposes immune tolerance for muscle transgene engraftment despite preexisting immunity","volume":"4","author":"Bartolo","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.03.037_bib182","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.transproceed.2005.03.070","article-title":"Long-term outcome of immunosuppression withdrawal after liver transplantation","volume":"37","author":"Girlanda","year":"2005","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.ymthe.2025.03.037_bib183","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1055\/s-0029-1192058","article-title":"Unique aspects of rejection and tolerance in liver transplantation","volume":"29","author":"Knechtle","year":"2009","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.ymthe.2025.03.037_bib184","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.4049\/jimmunol.172.2.1009","article-title":"Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition","volume":"172","author":"Pillarisetty","year":"2004","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib185","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/hep.22395","article-title":"Mechanism of T\u00a0cell tolerance induction by murine hepatic Kupffer cells","volume":"48","author":"You","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.03.037_bib186","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/hep.23043","article-title":"Hepatic regulatory T\u00a0cells and Kupffer cells are crucial mediators of systemic T\u00a0cell tolerance to antigens targeting murine liver","volume":"50","author":"Breous","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.03.037_bib187","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/0168-8278(95)80433-1","article-title":"Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge","volume":"22","author":"Knolle","year":"1995","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib188","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.4049\/jimmunol.1700540","article-title":"TLR2 Stimulation Strengthens Intrahepatic Myeloid-Derived Cell-Mediated T Cell Tolerance through Inducing Kupffer Cell Expansion and IL-10 Production","volume":"200","author":"Liu","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib189","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1189\/jlb.2AB0613-342RR","article-title":"Hepatocytes induce Foxp3(+) regulatory T\u00a0cells by Notch signaling","volume":"96","author":"Burghardt","year":"2014","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib190","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/bloodadvances.2024013000","article-title":"Induction of factor VIII tolerance by hemophilia gene transfer to eradicate factor VIII inhibitors","volume":"9","author":"Young","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.03.037_bib191","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ymthe.2024.03.016","article-title":"Immune tolerance induction by hepatic gene transfer: First-in-human evidence","volume":"32","author":"Kaczmarek","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib192","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.jtha.2023.05.011","article-title":"A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment?","volume":"21","author":"Valentino","year":"2023","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.03.037_bib193","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib194","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1182\/blood-2010-06-288001","article-title":"Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy","volume":"116","author":"Finn","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.037_bib195","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib196","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","article-title":"Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B","volume":"391","author":"Cuker","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib197","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/01926233241298892","article-title":"Systemic Toxicity of Recombinant Adeno-Associated Virus Gene Therapy Vectors","volume":"52","author":"Assaf","year":"2024","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib198","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(23)02874-X","article-title":"AAV1-hOTOF gene therapy for autosomal recessive deafness 9: a single-arm trial","volume":"403","author":"Lv","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.03.037_bib199","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101197","article-title":"First use of adeno-associated viruses in the human inner ear","volume":"32","author":"Landegger","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib200","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3389\/fphar.2014.00205","article-title":"Immune system of the inner ear as a novel therapeutic target for sensorineural hearing loss","volume":"5","author":"Okano","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib201","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fphar.2014.00287","article-title":"Inflammatory and immune responses in the cochlea: potential therapeutic targets for sensorineural hearing loss","volume":"5","author":"Fujioka","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib202","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.heares.2017.12.009","article-title":"Immune cells and non-immune cells with immune function in mammalian cochleae","volume":"362","author":"Hu","year":"2018","journal-title":"Hear. Res."},{"key":"10.1016\/j.ymthe.2025.03.037_bib203","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/cne.20619","article-title":"Mononuclear phagocytes migrate into the murine cochlea after acoustic trauma","volume":"489","author":"Hirose","year":"2005","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib204","doi-asserted-by":"crossref","DOI":"10.1038\/srep42079","article-title":"Gfi1(Cre) mice have early onset progressive hearing loss and induce recombination in numerous inner ear non-hair cells","volume":"7","author":"Matern","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.03.037_bib205","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/jnr.21625","article-title":"Bone marrow-derived cells expressing Iba1 are constitutively present as resident tissue macrophages in the mouse cochlea","volume":"86","author":"Okano","year":"2008","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.ymthe.2025.03.037_bib206","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.580639","article-title":"On the Role of Fibrocytes and the Extracellular Matrix in the Physiology and Pathophysiology of the Spiral Ligament","volume":"11","author":"Peeleman","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib207","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nbt.3781","article-title":"A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear","volume":"35","author":"Landegger","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib208","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41467-018-08243-1","article-title":"AAV2.7m8 is a powerful viral vector for inner ear gene therapy","volume":"10","author":"Isgrig","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.037_bib209","doi-asserted-by":"crossref","DOI":"10.1016\/j.heares.2023.108735","article-title":"Immune responses in the mammalian inner ear and their implications for AAV-mediated inner ear gene therapy","volume":"432","author":"Ishibashi","year":"2023","journal-title":"Hear. Res."},{"key":"10.1016\/j.ymthe.2025.03.037_bib210","doi-asserted-by":"crossref","DOI":"10.1016\/j.heares.2020.107930","article-title":"Preclinical testing of AAV9-PHP.B for transgene expression in the non-human primate cochlea","volume":"394","author":"Ivanchenko","year":"2020","journal-title":"Hear. Res."},{"key":"10.1016\/j.ymthe.2025.03.037_bib211","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fimmu.2019.00337","article-title":"Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics","volume":"10","author":"Gavriilaki","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.24953\/turkjped.2023.596","article-title":"Management of pediatric hemolytic uremic syndrome","volume":"66","author":"G\u00fclhan","year":"2024","journal-title":"Turk J. Pediatr."},{"key":"10.1016\/j.ymthe.2025.03.037_bib213","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in Secondary Thrombotic Microangiopathy","volume":"6","author":"Palma","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ymthe.2025.03.037_bib214","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.kint.2024.12.016","article-title":"The membrane attack complex drives thrombotic microangiopathy in complement mediated atypical hemolytic uremic syndrome","volume":"107","author":"Smith-Jackson","year":"2025","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2025.03.037_bib215","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173510","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"Salabarria","year":"2024","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.037_bib216","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.03.037_bib217","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib218","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib219","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","article-title":"Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy","volume":"44","author":"Day","year":"2021","journal-title":"Drug Saf."},{"key":"10.1016\/j.ymthe.2025.03.037_bib220","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","article-title":"Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib221","unstructured":"https:\/\/www.novartis.com\/news\/media-releases\/novartis-presents-new-data-safety-and-efficacy-zolgensma-including-maintained-and-improved-motor-milestones-older-and-heavier-children-sma."},{"key":"10.1016\/j.ymthe.2025.03.037_bib222","unstructured":"R., S., Toxicity risks of adeno-associated virus (AAV) vectors for gene therapy (GT). Presented at: FDA Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) Meeting #70, United States Food & Drug Administration, 2023."},{"key":"10.1016\/j.ymthe.2025.03.037_bib223","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s44321-024-00037-x","article-title":"Improved gene therapy for spinal muscular atrophy in mice using codon-optimized hSMN1 transgene and hSMN1 gene-derived promotor","volume":"16","author":"Xie","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib224","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","article-title":"Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial","volume":"22","author":"Shieh","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2023.131617","article-title":"Gene therapy vector-related myocarditis","volume":"398","author":"Silver","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib226","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.950651","article-title":"Drug development progress in duchenne muscular dystrophy","volume":"13","author":"Deng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib227","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib228","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/sj.gt.3303020","article-title":"Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts","volume":"14","author":"McTiernan","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib229","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1094279","article-title":"Immune transgene-dependent myocarditis in macaques after systemic administration of adeno-associated virus expressing human acid alpha-glucosidase","volume":"14","author":"Hordeaux","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib230","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib231","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba9188","article-title":"MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates","volume":"12","author":"Hordeaux","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib232","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.omtm.2022.01.013","article-title":"Characterization of AAV-mediated dorsal root ganglionopathy","volume":"24","author":"Buss","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib233","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1016\/j.ymthe.2024.07.016","article-title":"A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders","volume":"32","author":"Vrellaku","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib234","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.03.037_bib235","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib236","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1089\/hum.2013.238","article-title":"Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial","volume":"25","author":"Tardieu","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib237","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib238","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41591-021-01664-4","article-title":"AAV gene therapy for Tay-Sachs disease","volume":"28","author":"Flotte","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib239","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/TP.0b013e3182590d8f","article-title":"In\u00a0vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function","volume":"94","author":"Miroux","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.ymthe.2025.03.037_bib240","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1111\/j.1600-6143.2012.04269.x","article-title":"Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients","volume":"12","author":"Akimova","year":"2012","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.ymthe.2025.03.037_bib241","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.omtm.2023.06.001","article-title":"Adeno-associated virus-mediated gene therapy in a patient with Canavan disease using dual routes of administration and immune modulation","volume":"30","author":"Corti","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib242","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.ymthe.2025.03.037_bib243","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series","volume":"231","author":"Chand","year":"2021","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.ymthe.2025.03.037_bib244","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.omtm.2019.05.012","article-title":"Enhancement of Adeno-Associated Virus-Mediated Gene Therapy Using Hydroxychloroquine in Murine and Human Tissues","volume":"14","author":"Chandler","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib245","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1172\/JCI8317","article-title":"Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus","volume":"105","author":"Duan","year":"2000","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.037_bib246","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/mt.2009.257","article-title":"Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction","volume":"18","author":"Finn","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib247","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging Issues in AAV-Mediated In\u00a0Vivo Gene Therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib248","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/mt.2010.170","article-title":"Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application","volume":"18","author":"Monahan","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib249","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/gt.2008.137","article-title":"Enhancing transduction of the liver by adeno-associated viral vectors","volume":"16","author":"Nathwani","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib250","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s12640-014-9514-8","article-title":"Toxic effects of bortezomib on primary sensory neurons and Schwann cells of adult mice","volume":"27","author":"Al\u00e9","year":"2015","journal-title":"Neurotox Res."},{"key":"10.1016\/j.ymthe.2025.03.037_bib251","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.neuro.2014.02.001","article-title":"Neurotoxicity induced by antineoplastic proteasome inhibitors","volume":"43","author":"Al\u00e9","year":"2014","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ymthe.2025.03.037_bib252","doi-asserted-by":"crossref","first-page":"194ra92","DOI":"10.1126\/scitranslmed.3005795","article-title":"Overcoming preexisting humoral immunity to AAV using capsid decoys","volume":"5","author":"Mingozzi","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib253","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ymthe.2019.11.014","article-title":"The Effect of CpG Sequences on Capsid-Specific CD8(+) T Cell Responses to AAV Vector Gene Transfer","volume":"28","author":"Xiang","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib254","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/hum.2014.106","article-title":"Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial","volume":"26","author":"Monahan","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib255","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2013.9","article-title":"Empty Virions In AAV8 Vector Preparations Reduce Transduction Efficiency And May Cause Total Viral Particle Dose-Limiting Side-Effects","volume":"1","author":"Gao","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib256","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/mt.2011.108","article-title":"A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8","volume":"19","author":"Monteilhet","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib257","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41598-020-57893-z","article-title":"Capsid-specific removal of circulating antibodies to adeno-associated virus vectors","volume":"10","author":"Bertin","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.03.037_bib258","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.omtm.2020.01.004","article-title":"Successful Transduction with AAV Vectors after Selective Depletion of Anti-AAV Antibodies by Immunoadsorption","volume":"16","author":"Orlowski","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib259","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/jca.22069","article-title":"Efficient removal of antibodies to adeno-associated viruses by immunoadsorption","volume":"38","author":"Boedecker-Lips","year":"2023","journal-title":"J.\u00a0Clin. Apher."},{"key":"10.1016\/j.ymthe.2025.03.037_bib260","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/mt.2012.258","article-title":"Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors","volume":"21","author":"Mimuro","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib261","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in\u00a0vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib262","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139881","article-title":"Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme","volume":"5","author":"Elmore","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.03.037_bib263","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1612567","article-title":"IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation","volume":"377","author":"Jordan","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.037_bib264","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/j.ymthe.2024.05.004","article-title":"Engineered IgM and IgG cleaving enzymes for mitigating antibody neutralization and complement activation in AAV gene transfer","volume":"32","author":"Smith","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib265","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1089\/hum.2022.216","article-title":"Neonatal Fc Receptor Inhibition Enables Adeno-Associated Virus Gene Therapy Despite Pre-Existing Humoral Immunity","volume":"34","author":"Horiuchi","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib266","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1517\/14712598.2015.1035645","article-title":"Strategies to circumvent humoral immunity to adeno-associated viral vectors","volume":"15","author":"Tse","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib267","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40265-023-01836-1","article-title":"Mitigating Serious Adverse Events in Gene Therapy with AAV Vectors: Vector Dose and Immunosuppression","volume":"83","author":"Ertl","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2025.03.037_bib268","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.tibtech.2022.11.006","article-title":"Evading and overcoming AAV neutralization in gene therapy","volume":"41","author":"Earley","year":"2023","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib269","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2014.33","article-title":"B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study","volume":"1","author":"Corti","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib270","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/gt.2012.55","article-title":"Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue","volume":"20","author":"Mingozzi","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib271","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101216","article-title":"B cell focused transient immune suppression protocol for efficient AAV readministration to the liver","volume":"32","author":"Rana","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib272","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/mt.2012.84","article-title":"Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B","volume":"20","author":"Mingozzi","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib273","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1089\/hum.2021.258","article-title":"The Effect of Rapamycin and Ibrutinib on Antibody Responses to Adeno-Associated Virus Vector-Mediated Gene Transfer","volume":"33","author":"Xiang","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib274","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.mt.6300377","article-title":"Transient immunomodulation allows repeated injections of AAV1 and correction of muscular dystrophy in multiple muscles","volume":"16","author":"Lorain","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib275","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1089\/hum.2021.129","article-title":"Repeated Systemic Dosing of Adeno-Associated Virus Vectors in Immunocompetent Mice After Blockade of T Cell Costimulatory Pathways","volume":"33","author":"Zhong","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib276","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/jth.14757","article-title":"Blockade of the costimulatory CD28-B7 family signal axis enables repeated application of AAV8 gene vectors","volume":"18","author":"Frentsch","year":"2020","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.03.037_bib277","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/mt.2012.101","article-title":"MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV","volume":"20","author":"Sudres","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib278","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/s41556-020-0563-3","article-title":"Synthetic immunomodulation with a CRISPR super-repressor in\u00a0vivo","volume":"22","author":"Moghadam","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib279","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.037_bib280","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd0321","article-title":"Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles","volume":"7","author":"Ilyinskii","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2025.03.037_bib281","article-title":"Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy","volume":"5","author":"Weber","year":"2023","journal-title":"JHEP Rep."},{"key":"10.1016\/j.ymthe.2025.03.037_bib282","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.omtm.2021.06.015","article-title":"ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia","volume":"22","author":"Ilyinskii","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib283","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101363","article-title":"Repeated dosing of AAV-mediated liver gene therapy in juvenile rat and mouse models of Crigler-Najjar syndrome type I","volume":"32","author":"Shi","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.037_bib284","doi-asserted-by":"crossref","first-page":"pgad394","DOI":"10.1093\/pnasnexus\/pgad394","article-title":"Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents","volume":"2","author":"Ilyinskii","year":"2023","journal-title":"PNAS Nexus"},{"key":"10.1016\/j.ymthe.2025.03.037_bib285","first-page":"19","article-title":"Functional Assessment of T Cell Responses to AAV8 Empty Capsids in Healthy Volunteers Abstract #37","volume":"30","author":"Schroeder","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib286","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/mt.2013.166","article-title":"Modulation of CD8+ T\u00a0cell responses to AAV vectors with IgG-derived MHC class II epitopes","volume":"21","author":"Hui","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib287","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.3748\/wjg.v18.i32.4288","article-title":"Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis","volume":"18","author":"van der Marel","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib288","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2016-07-727834","article-title":"FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII","volume":"129","author":"Yoon","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.037_bib289","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104216","article-title":"CD4(+) T\u00a0cells engineered with FVIII-CAR and murine Foxp3 suppress anti-factor VIII immune responses in hemophilia a mice","volume":"358","author":"Fu","year":"2020","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib290","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.ymthe.2021.04.034","article-title":"CAR- and TRuC-redirected regulatory T\u00a0cells differ in capacity to control adaptive immunity to FVIII","volume":"29","author":"Rana","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.037_bib291","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3389\/fimmu.2019.00274","article-title":"Reprogrammed CD4(+) T Cells That Express FoxP3(+) Control Inhibitory Antibody Formation in Hemophilia A Mice","volume":"10","author":"Herzog","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib292","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.4049\/jimmunol.1701800","article-title":"Targeting Antigen-Specific B Cells Using Antigen-Expressing Transduced Regulatory T Cells","volume":"201","author":"Zhang","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2025.03.037_bib293","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3389\/fimmu.2020.00693","article-title":"Suppression of FVIII-Specific Memory B Cells by Chimeric BAR Receptor-Engineered Natural Regulatory T Cells","volume":"11","author":"Pohl","year":"2020","journal-title":"Front. Immunol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:36:27Z","timestamp":1792686987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625002114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":293,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1525001625002114"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.037","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The curious case of AAV immunology","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}